Colorectal cancer: using blood samples and tumor tissue to detect K-ras mutations
Publication in refereed journal

Times Cited
Web of Science5WOS source URL (as at 15/09/2021) Click here for the latest count
Altmetrics Information

Other information
AbstractWe performed a meta-analysis to assess whether blood can be substituted for tumor tissue in K-ras mutation testing. PubMed, EMBASE, MEDLINE, and BIOSIS databases were searched. Twenty-three studies including 1261 patients were included. The pooled overall sensitivity, specificity, and concordance rate were 0.69 (95% CI: 0.59-0.78), 0.96 (95% CI: 0.93-0.97), and 0.86 (95% CI: 0.82-0.89), respectively. Subgroup analysis indicated that plasma (sensitivity: 0.74; mutation rate: 0.34) exhibited superior sensitivity compared with serum (sensitivity: 0.45; mutation rate: 0.24). We conclude that blood is a suitable substitute for tumor tissue in K-ras mutation testing. K-ras mutation positivity in blood can be used to identify patients who should not receive EGFR monoclonal antibody therapy, but the absence of blood positivity does not necessarily imply negativity.
All Author(s) ListLi Y, Fu XH, Yuan JQ, Yang ZY, Mao C, Dong XM, Tang JL, Wang SY
Journal nameExpert Review of Anticancer Therapy
Volume Number15
Issue Number6
Pages715 - 725
LanguagesEnglish-United Kingdom
Keywordsblood; colorectal cancer; diagnostic test; K-ras; meta-analysis; mutation; plasma; serum
Web of Science Subject CategoriesOncology

Last updated on 2021-16-09 at 01:04